Résztvevőt keres3. fázis
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients with Myotonic Dystrophy Type 1 and Type 2 who have completed the MEX-DM-302 Study (ATLAS Study)
A legfontosabb adatok
- Ki végzi
- Lupin Atlantis Holdings SA
- Hol
- Belgium, Dánia, Németország, Olaszország és Spanyolország13 helyszín, 5 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Fázis
- 3. fázis
- Résztvevők
- 146 fő, tervezett
- Kezdés
- 2025. szept. 12.
- Várható befejezés
- 2029. jan. 31.
- A vizsgálat típusa
- Beavatkozással járó
- A regiszteradat frissítve
- 2026. november 10.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for people with myotonic dystrophy type 1 or type 2 who have completed the MEX-DM-302 study. They will take mexiletine PR once daily for muscle stiffness (myotonia).
- Életkor
- 16 years and older
- Nem
- Men, and women who are not pregnant
- A betegség stádiuma
- DM1 or DM2 confirmed by a gene test. People with DM1 need a muscle impairment (MIRS) score of 2, 3 or 4. Hand grip must be strong enough to hold the test device. BMI 18.5 kg/m2 to 30 kg/m2 and weight ≥45 kg (99 lb).
- Korábbi kezelés
- Must have completed the MEX-DM-302 study. No anti-myotonic treatment (such as metformin, propafenone, flecainide, lamotrigine, carbamazepine) within 4 weeks before the start or 5 half-lives, whichever is longer.
- Biomarker vagy leletérték
- Genetic confirmation of DM1 or DM2.
A részvétel fő kizáró okai
- Pregnant or breastfeeding
- Significant heart problems, heart rhythm problems, a pacemaker or an implanted defibrillator
- Using a wheelchair all the time or being bed-ridden
- Allergy to mexiletine or local anesthetics
- Severe kidney problems (GFR < 30 mL/min), uncontrolled diabetes, recent cancer, multiple sclerosis or seizures
A regiszter feltételei, szó szerint
Mind a 24 feltétel megnézéseKevesebb
Ki vehet részt
- DM1 or DM2 diagnosis confirmed genetically
- Ability to comprehend and willingness to sign an informed consent (ICF) or ICF of the parent(s)/legal guardian and written assent from the patient (if patient < 18 years of age)
- Ability to understand the study requirements including intention to stay in the study until the end-of-study visit at 26 weeks of treatment
- Male or non-pregnant female ≥16 years of age
- Body Mass Index (BMI) of 18.5 kg/m2 to 30 kg/m2, and weight ≥45 kg
- Female patients of childbearing potential must be using a highly effective form of birth control for the duration of the study and for at least 7 days after last dose of study drug
- No significant cardiac abnormalities as determined by a cardiologist’s assessment
- Have sufficient finger flexor strength to grasp the handle of the dynamometer used to measure myotonia
- DM1 patients only - Muscular impairment rating scale (MIRS) score of 2, 3 or 4
Ki nem vehet részt
- Intake of any anti-myotonic treatment within 4 weeks prior to baseline (Day 1) or 5 half-lives, whichever is longer such as metformin, such as propafenone, flecainide, lamotrigine, carbamazepine or any other channel-blocker/ anticonvulsive drugs
- Use of any concomitant medications that could increase the cardiac risk
- Participation in another interventional clinical study during the last 3 months or 5 half-lives of the investigational medicinal product, whichever is longer (with the exception of participation in the previous MEX-DM-302 study)
- Have any one of the following medical conditions: uncontrolled diabetes mellitus, cancer other than skin cancer less than five years previously (e.g., basal-cell carcinoma (BCC) and squamous-cell carcinoma (SCC) of skin allowed), multiple sclerosis, seizure disorders, or other serious medical illness
- Known allergy to mexiletine or any local anesthetics
- Medical conditions which could interfere with muscle function such as infections, trauma, fractures, or planned surgery
- Medical conditions that could affect hand functioning including but not limited to rheumatoid arthritis, Dupuytren’s contracture, hand deformity, etc
- Severe arthritis or medical condition (other thanDM1/DM2) that would significantly impact ambulation
- Any cardiac safety associated condition including any of the following criteria detected by cardiac evaluations including 24-hr Holter monitor, echocardiogram and clinical evaluations: • PR interval ≥240 ms or QRS duration ≥120 ms on resting ECG • Personal history of 3rd degree or 2nd degree type 2 atrioventricular block or sinus node dysfunction with pauses ≥3 seconds, complete bundle branch block, bifascicular and trifascicular block or any heart block susceptible to evolve to complete heart block • Personal history of sustained atrial fibrillation, flutter or tachycardia (duration >30 seconds) • Personal history of non-sustained (ventricular triplets or more) or sustained ventricular tachycardia • Myocardial infarction (acute or past) or coronary artery stenosis >50%, presence of abnormal Q waves • New York Heart Association (NYHA) Class II to IV heart failure • Left ventricular systolic dysfunction with ejection fraction <50% • Sinus node dysfunction (including ECG sinus rate <50 beats per minute (BPM)) • Co-administration of antiarrhythmics inducing torsades de pointes (class Ia: quinidine, procainamide, disopyramide, ajmaline; class Ic: encainide, flecainide, propafenone, moricizine; class III: amiodarone, sotalol, ibutilide, dofetilide, dronedarone, vernakalant) • Co-administration of other classes of antiarrhythmics (class Ib: lidocaine, phenytoin, tocainide; class II: propranolol, esmolol, timolol, metoprolol, atenolol, carvedilol, bisoprolol, nebivolol; class IV: verapamil, diltiazem) • Patients with implantable cardioverter defibrillators (ICDs) and pacemakers are excluded • Presence of symptomatic coronary artery disease
- Severe renal impairment (glomerular filtration rate (GFR) < 30 mL/min)
- Preexisting elevated liver function tests > 3 times the upper limit of normal (ULN) on Day 1 (alanine transaminase (ALT)/aspartate transaminase (AST), gamma-glutamyl transferase (GGT)) and/or any abnormal chemistry, hematology or urine lab considered clinically significant by investigator
- Serum potassium values < 3.5 mmol/L or > 5.0 mmol/L or serum magnesium values < 1.7 mg/dL. Electrolytic imbalance such as hypokalaemia, hyperkalaemia or hypomagnesaemia may increase the proarrhythmic effects of mexiletine. Electrolyte imbalances need to be corrected before administering mexiletine and will be monitored throughout treatment
- Are pregnant or lactating
- Wheelchair-bound or bed-ridden
- High incidence of falls or fall-associated fractures (>5 falls during the past 12 months)
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
5 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
To assess the continuous long-term safety and efficacy of mexiletine PR for the symptomatic treatment of myotonia in patients with myotonic dystrophy type 1 and type 2 who have completed MEX-DM-302 study.
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- Hivatalos cím
- An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients with Myotonic Dystrophy Type 1 and Type 2 who have completed the MEX-DM-302 Study.
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
- A regiszteradat frissítve
- 2026. november 10.